Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Net Margin (2017 - 2025)

UroGen Pharma (URGN) has disclosed Net Margin for 9 consecutive years, with 69.68% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 8303.0% year-over-year to 69.68%, compared with a TTM value of 139.81% through Dec 2025, up 54.0%, and an annual FY2025 reading of 139.81%, up 54.0% over the prior year.
  • Net Margin was 69.68% for Q4 2025 at UroGen Pharma, up from 121.34% in the prior quarter.
  • Across five years, Net Margin topped out at 69.68% in Q4 2025 and bottomed at 346.49% in Q1 2021.
  • Average Net Margin over 5 years is 168.52%, with a median of 160.61% recorded in 2022.
  • The sharpest move saw Net Margin soared 822594bps in 2021, then tumbled -5335bps in 2025.
  • Year by year, Net Margin stood at 175.91% in 2021, then rose by 9bps to 159.57% in 2022, then skyrocketed by 31bps to 110.57% in 2023, then tumbled by -38bps to 152.71% in 2024, then soared by 54bps to 69.68% in 2025.
  • Business Quant data shows Net Margin for URGN at 69.68% in Q4 2025, 121.34% in Q3 2025, and 206.24% in Q2 2025.